Benitec Biopharma
BNTC
25 hedge funds and large institutions have $127M invested in Benitec Biopharma in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 0 closing their positions.
186% more capital invested
Capital invested by funds: $44.3M → $127M (+$82.5M)
62.06% more ownership
Funds ownership: 67.82% → 129.88% (+62%)
32% more funds holding
Funds holding: 19 → 25 (+6)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$63.9M |
| 2 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$584K |
| 3 |
AC
Armistice Capital
New York
|
+$537K |
| 4 |
LPC
Lion Point Capital
New York
|
+$349K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$267K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$217K |
| 2 |
Morgan Stanley
New York
|
-$38.3K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$29.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.91K |
BNTC Hedge Fund Activity: Q3 2024 in Review
25 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2024, worth a combined $127M — up 186% from $44.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BNTC positions and 0 closed out — a net gain of 6 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $63.9M. The largest seller was Janus Henderson Group, cutting an estimated $217K.
- 25 institutional investors held Benitec Biopharma (BNTC) as of Q3 2024, up from 19 in Q2 2024.
- Funds reported $127M of Benitec Biopharma stock for Q3 2024, up 186% quarter-over-quarter.
- 6 funds opened new Benitec Biopharma positions in Q3 2024 and 0 closed out, a net change of +6 holders.
- The largest Benitec Biopharma buyer in Q3 2024 was Suvretta Capital Management, an estimated $63.9M added.
- The largest Benitec Biopharma seller in Q3 2024 was Janus Henderson Group, an estimated $217K sold.
Based on aggregated 13F filings for Q3 2024.